Therapeutic Response

RET p.M918T status confers therapeutic sensitivity to Selpercatinib in patients with Medullary Thyroid Cancer.

Statements

Source and description

Retsevmo (selpercatinib) [product information]. EMA. The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET-mutant medullary thyroid cancer. This indication is based on LIBRETTO-001 (a phase 1/2, multicenter, open-label, single-arm clinical study), where the most common variant was p.M918T, followed by extracelluar cysteine mutations.